OVID Ovid Therapeutics

Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress

Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress
EN
12/10/2020

Underlying

OVIDOvid Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ovid Therapeutics

Laura Chico
  • Laura Chico
OVID OVID THERAPEUTICS
10/03/25 October 3, 2025 1 EN
 PRESS RELEASE
Free
OVID Ovid Therapeuti...

Ovid Therapeutics Announces Pricing of Private Placement Totaling up t...

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a securities purchase agreem...

October 3, 2025 1 EN
 PRESS RELEASE
Free
OVID Ovid Therapeuti...

Ovid announces positive topline results for the next-generation GABA-a...

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves bi...

October 3, 2025 1 EN
Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
HOV HOVNANIAN ENTERPRISES INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
LRMR INC.
TVTX LARIMAR THERAPEUTICS INC
VRDN TRAVERE THERAPEUTICS INC
STX VIRIDIAN THERAPEUTICS INC
ATXS SEAGATE TECHNOLOGY HLDGS PLC
GFS ASTRIA THERAPEUTICS INC
SLDB GLOBALFOUNDRIES INC
DNTH SOLID BIOSCIENCES INC
TLX DIANTHUS THERAPEUTICS INC
MAZE TELIX PHARMACEUTICALS LIMITED
BBOT MAZE THERAPEUTICS INC
BRIDGEBIO ONCOLOGY THERAPEUTICS
08/18/25 August 18, 2025 1 EN
Laura Chico
  • Laura Chico
ARDX ARDELYX INC
OVID OVID THERAPEUTICS
STOK STOKE THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
ATXS ASTRIA THERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
DNTH DIANTHUS THERAPEUTICS INC
MAZE MAZE THERAPEUTICS INC
08/18/25 August 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch